Impact of prosthesis-patient mismatch after mitral valve replacement in rheumatic population: Does mitral position

Seung Hyun Lee1, Byung Chul Chang1, Young-Nam Youn1

  • 1Division of Thoracic and Cardiovascular Surgery, Severance Cardiovascular Hospital, Yonsei Cardiovascular Research Institute, Yonsei University, College of Medicine, 250 Seongsanno, Seodaemun-gu, Seoul, 03722, Republic of Korea.

Abstract

Insights

Prosthesis-patient mismatch (PPM) after mitral valve replacement in rheumatic patients did not significantly impact long-term outcomes. This study found no association between PPM and adverse remodeling or survival rates.

Area of Science:

  • Cardiovascular Surgery
  • Cardiac Surgery Outcomes
  • Prosthetic Heart Valves

Background:

  • Prosthesis-patient mismatch (PPM) occurs when an implanted heart valve is too small for the patient's body surface area (BSA).
  • Rheumatic heart disease remains a significant cause of mitral valve disease globally, necessitating mitral valve replacement (MVR).

Purpose of the Study:

  • To investigate the long-term clinical outcomes in rheumatic patients undergoing MVR.
  • To determine the impact of PPM on post-MVR remodeling, survival, and tricuspid regurgitation (TR) progression.

Main Methods:

  • A cohort of 445 patients with rheumatic disease undergoing isolated MVR between 2000 and 2013 were analyzed.
  • Effective orifice area (EOA) was measured, and PPM was defined as indexed EOA (EOA/BSA) ≤ 1.2 cm²/m².
  • Clinical and echocardiographic data were collected for a mean follow-up of 8.7 years.

Main Results:

  • 37% of patients experienced PPM. No significant baseline differences were observed between groups, except for age and indexed EOA.
  • Both groups showed a decrease in mean trans-valvular pressure gradient (MPG) and left atrial/ventricular dimensions post-MVR, without significant inter-group differences.
  • Freedom from TR progression and overall survival rates at 3 and 5 years were similar between patients with and without PPM.

Conclusions:

  • Mitral valve prosthesis-patient mismatch (PPM) in rheumatic patients undergoing MVR does not appear to be associated with adverse atrial or ventricular remodeling.
  • PPM did not significantly influence late clinical outcomes, including survival and tricuspid regurgitation progression.

Related Concept Videos

Mitral Valve Prolapse I: Introduction01:27

Mitral Valve Prolapse I: Introduction

IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
651
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
827
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
335
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
736
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
662
Mitral Stenosis IV: Nursing Management01:27

Mitral Stenosis IV: Nursing Management

A comprehensive nursing assessment is essential for patients with valvular heart disease, which involves any dysfunction of the heart valves that could impact blood flow and overall heart function.Subjective Data Collection:Chief Complaint and Present Illness: Start with the patient's primary concerns, focusing on the onset, duration, and progression of cardiac symptoms such as dyspnea, fatigue, chest pain, and palpitations.Past Medical History: Collect detailed information on any previous...
307